Corbus reports Phase 1 data for CRB-701 at ASCO: 44% ORR in mUC, 43% in cervical cancer

Corbus Pharmaceuticals Holdings, Inc.

44% ORR and 78% DCR in mUC (n=9), 43% ORR and 86% DCR in cervical cancer (n=7) at doses ≥1.2 mg/Kg.
No DLTs or grade 4/5 AEs observed to date; single grade 1 neuropathy (resolved) and 3 skin rashes (resolved).
Free MMAE levels lower than enfortumab vedotin across all doses up to 4.5 mg/Kg.
Enrollment expanded to 37 patients (25 evaluable); US phase 1 completing Q4 2024, data Q1 2025.
Preventative eye measures introduced after two grade 3 corneal disorders; no further cases at 4.5 mg/Kg.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.